Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer

Next Previous
Trial Profile

A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms JAVELIN Solid Tumor Japan
  • Sponsors Merck KGaA; Merck Serono

Most Recent Events

  • 17 Dec 2021 Results from pooled data from JAVELIN 62 Merkel 200, JAVELIN Solid Tumor, and JAVELIN Solid Tumor JPN assessing (PK)-tumor growth dynamics (TGD) analysis published in the Clinical Cancer Research
  • 21 Oct 2019 Status changed from active, no longer recruiting to completed.
  • 25 Sep 2019 Results assessing pharmacokinetic/ pharmacodynamic analyses for avelumab comparing weight-based dosing from 3 clinical trials (NCT01772004, NCT01943461, and NCT02155647) published in the Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top